PDS Biotechnology Corporation

About:

PDS Biotechnology Announces Treatment of First Patient with PDS0101.

Top Investors: Horizon Technology Finance

Description:

PDS Biotechnology Corporation is a biopharmaceutical company. It develops immunotherapies for cancer and other infectious diseases. It develops products to prevent and treat cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, vulvar, and penile cancers. The company offers PDS0101, a treatment for HPV-related cancers; PDS0102, a pandemic influenza vaccine; and PDS0103, a line of immunotherapy products for non-viral cancers. PDS Biotechnology Corporation was founded in 2005 and is headquartered in North Brunswick, New Jersey.

Total Funding Amount:

$57M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

North Brunswick, New Jersey, United States

Founded Date:

2005-01-01

Founders:

Gregory L. Conn

Number of Employees:

11-50

Last Funding Date:

2022-08-24

IPO Status:

Public

Industries: